Literature DB >> 22570167

Distinct genetic alterations in pediatric glioblastomas.

Sun-ju Byeon1, Jae Kyung Myung, Se Hoon Kim, Seung-Ki Kim, Ji Hoon Phi, Sung-Hye Park.   

Abstract

BACKGROUND: Pediatric high-grade tumors, especially glioblastomas (GBs), can be clinically devastating but are under-studied in comparison with adult GBs (aGBs). Molecular features of pediatric GBs (pGBs) are poorly understood and novel-targeted therapies have not been routinely used in pediatric patients with GBs.
METHODS: Twenty-four non-brainstem pGBs were studied. To compare pGBs with aGBs, immunohistochemical staining and fluorescent in situ hybridization were performed in paraffin-embedded tissues. Microarray gene expression analyses were performed in snap-frozen tissues of four primary pGBs, six primary aGBs, and one non-neoplastic brain.
RESULTS: Immunohistochemial p16 loss was more frequent in pGBs, whereas p53, epidermal growth factor receptor, and phosphatase and tensin homolog loss were similar to that of aGBs. No case was isocitrate dehydrogenase (IDH)1 immunopositive or showed the IDH1 R132/IDH2 R172 mutation, suggesting primary GB. Microarray analysis revealed two pGB subtypes (A and B). Type B pGBs and aGBs had similar gene expression profiles; however, the profiles of type A pGBs differed from those of aGBs. In type A pGBs, we identified 90 up- and 63 down-regulated genes; platelet-derived growth factor receptor α polypeptide and CCND2 expression were significantly reduced, whereas they were up-regulated in aGBs.
CONCLUSIONS: Our study found two distinct pGB gene expression profiles: one similar to that of aGBs and the other different. We identified significantly up- and down-regulated genes in pGBs that may provide better targets for diagnostic, prognostic, and therapeutic uses; however, more studies are required to determine the classification and optimal treatment of pediatric patients with GBs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22570167     DOI: 10.1007/s00381-012-1773-1

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  22 in total

1.  Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients.

Authors:  P M Ganigi; V Santosh; B Anandh; B A Chandramouli; V R Sastry Kolluri
Journal:  Pediatr Neurosurg       Date:  2005 Nov-Dec       Impact factor: 1.162

Review 2.  Brain tumors in children.

Authors:  R J Packer
Journal:  Arch Neurol       Date:  1999-04

3.  Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.

Authors:  Sumihito Nobusawa; Robert Stawski; Young-Ho Kim; Yoichi Nakazato; Hiroko Ohgaki
Journal:  Neuropathology       Date:  2011-03-07       Impact factor: 1.906

4.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

5.  Pediatric glioblastomas: a histopathological and molecular genetic study.

Authors:  Vaishali Suri; Prasenjit Das; Pankaj Pathak; Ayushi Jain; Mehar Chand Sharma; Sachin Anil Borkar; Ashish Suri; Deepak Gupta; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2008-11-03       Impact factor: 12.300

Review 6.  Genetic alterations and signaling pathways in the evolution of gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Cancer Sci       Date:  2009-08-06       Impact factor: 6.716

7.  EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.

Authors:  Dorine A Bax; Nathalie Gaspar; Suzanne E Little; Lynley Marshall; Lara Perryman; Marie Regairaz; Marta Viana-Pereira; Raisa Vuononvirta; Swee Y Sharp; Jorge S Reis-Filho; João N Stávale; Safa Al-Sarraj; Rui M Reis; Gilles Vassal; Andrew D J Pearson; Darren Hargrave; David W Ellison; Paul Workman; Chris Jones
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

8.  High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.

Authors:  Dong Yin; Seishi Ogawa; Norihiko Kawamata; Patrizia Tunici; Gaetano Finocchiaro; Marica Eoli; Christian Ruckert; Thien Huynh; Gentao Liu; Motohiro Kato; Masashi Sanada; Anna Jauch; Martin Dugas; Keith L Black; H Phillip Koeffler
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

9.  Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10.

Authors:  A E Karlbom; C D James; J Boethius; W K Cavenee; V P Collins; M Nordenskjöld; C Larsson
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

10.  Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis.

Authors:  Russell K Hales; Ori Shokek; Peter C Burger; Nina P Paynter; Kaisorn L Chaichana; Alfredo Quiñones-Hinojosa; George I Jallo; Kenneth J Cohen; Danny Y Song; Benjamin S Carson; Moody D Wharam
Journal:  J Neurooncol       Date:  2009-12-31       Impact factor: 4.130

View more
  5 in total

Review 1.  Vaccination strategies for neuro-oncology.

Authors:  John H Sampson; Duane A Mitchell
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 2.  TET family proteins: oxidation activity, interacting molecules, and functions in diseases.

Authors:  Xingyu Lu; Boxuan Simen Zhao; Chuan He
Journal:  Chem Rev       Date:  2015-02-12       Impact factor: 60.622

3.  Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted population-based analysis.

Authors:  Hadie Adams; Hieab H H Adams; Christina Jackson; Jordina Rincon-Torroella; George I Jallo; Alfredo Quiñones-Hinojosa
Journal:  Childs Nerv Syst       Date:  2016-01-15       Impact factor: 1.475

Review 4.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Authors:  Chunzhi Zhang; Lynette M Moore; Xia Li; W K Alfred Yung; Wei Zhang
Journal:  Neuro Oncol       Date:  2013-07-21       Impact factor: 13.029

Review 5.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.

Authors:  Julie-Aurore Losman; William G Kaelin
Journal:  Genes Dev       Date:  2013-04-15       Impact factor: 12.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.